These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19051818)

  • 1. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
    Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
    Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
    Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.
    Yamada SD; Burger RA; Brewster WR; Anton D; Kohler MF; Monk BJ
    Cancer; 2000 Jun; 88(12):2782-6. PubMed ID: 10870061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
    Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K
    Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy and prognosis in uterine carcinosarcoma.
    Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
    J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma.
    Galaal K; Kew FM; Tam KF; Lopes A; Meirovitz M; Naik R; Godfrey KA; Hatem MH; Edmondson RJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Apr; 143(2):88-92. PubMed ID: 19201517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
    McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
    Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
    Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
    Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.
    Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B
    Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
    Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
    Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
    Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.